stockrowBecton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.
- Revenue
- −9.55%
- EPS
- −31.5%
- Free cash flow
- −31.6%
- Total debt
- −22.9%
Quarter to June 2026, against a year earlier
Follow BDX
Alert me
Becton, Dickinson and Company (BDX) EBITDA
Becton, Dickinson and Company's EBITDA for fiscal 2025 was $5.0B, up 7.60% from $4.7B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.8B. Over the past ten years it has ranged from $2.0B (fiscal 2015) to $5.0B (fiscal 2025) — the current reading is the highest in ten years. Becton, Dickinson and Company ranks 2nd of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $5.0B | 7.60% |
| FY2024 | $4.7B | 6.48% |
| FY2023 | $4.4B | (2.50%) |
| FY2022 | $4.5B | 0.69% |
| FY2021 | $4.5B | 48.03% |
| FY2020 | $3.0B | (24.57%) |
| FY2019 | $4.0B | 15.08% |
| FY2018 | $3.5B | 33.60% |
| FY2017 | $2.6B | 2.59% |
| FY2016 | $2.5B | 29.47% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.2B | 100.00% |
| Mar 2026 | $613.0M | (47.38%) |
| Dec 2025 | $1.2B | (33.69%) |
| Sep 2025 | $1.8B | 33.71% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MDLN Medline Inc. compare | $10.0B |
| BDX Becton, Dickinson and Company | $4.8B |
| ISRG Intuitive Surgical, Inc. compare | $4.1B |
| ALC Alcon compare | $2.7B |
| SOLV Solventum Corporation compare | $2.6B |
| RMD ResMed Inc. compare | $2.1B |
| BAX Baxter International Inc. compare | $1.5B |
| WST West Pharmaceutical Services, Inc. compare | $964.5M |
| COO The Cooper Companies, Inc. compare | $928.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BDX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement